The MEIP chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the MEIP chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The MEIP stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
View MEIP Detailed Price Forecast - CNN Money | View MEIP Detailed Summary - Google Finance | ||
View MEIP Detailed Summary - Yahoo! Finance | View MEIP Stock Research & Analysis - Zacks.com |
View MEIP Trends & Analysis - Trade-Ideas | View MEIP Major Holders - Barrons | ||
View MEIP Call Transcripts - NASDAQ | View MEIP Breaking News & Analysis - Seeking Alpha | ||
View MEIP Annual Report - CompanySpotlight.com | View MEIP OTC Short Report - OTCShortReport.com | ||
View MEIP Fundamentals - TradeKing | View MEIP SEC Filings - Bar Chart | ||
View Historical Prices for MEIP - The WSJ | View Performance/Total Return for MEIP - Morningstar | ||
View the Analyst Estimates for MEIP - MarketWatch | View the Earnings History for MEIP - CNBC | ||
View the MEIP Earnings - StockMarketWatch | View MEIP Buy or Sell Recommendations - MacroAxis | ||
View the MEIP Bullish Patterns - American Bulls | View MEIP Short Pain Metrics - ShortPainBot.com |
View MEIP Stock Mentions - StockTwits | View MEIP Stock Mentions - PennyStockTweets | ||
View MEIP Stock Mentions - Twitter | View MEIP Investment Forum News - Investor Hub | ||
View MEIP Stock Mentions - Yahoo! Message Board | View MEIP Stock Mentions - Seeking Alpha |
View Insider Transactions for MEIP - SECform4.com | View Insider Transactions for MEIP - Insider Cow | ||
View MEIP Major Holdings Summary - CNBC | View Insider Disclosure for MEIP - OTC Markets | ||
View Insider Transactions for MEIP - Yahoo! Finance | View Institutional Holdings for MEIP - NASDAQ |
View MEIP Stock Insight & Charts - FinViz.com | View MEIP Investment Charts - StockCharts.com | ||
View MEIP Stock Overview & Charts - BarChart | View MEIP User Generated Charts - Trading View |
MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344
Posted on Thursday April 11, 2024
SAN DIEGO, April 11, 2024--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported that the Company’s Board of Directors unanimously agreed on a strategic plan to leverage recent positive voruciclib and ME-344 clinical data to prioritize clinical development of voruciclib while enabling development of a new ME-344 formulation for Phase 1 study. Additionall
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
Posted on Thursday April 11, 2024
SAN DIEGO, April 11, 2024--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported that 25% of evaluable patients with relapsed metastatic colorectal cancer ("mCRC") in Cohort 1 of the ongoing Phase 1b study evaluating ME-344, an investigational inhibitor of mitochondrial oxidative phosphorylation ("OXPHOS"), in combination with bevacizumab (Avastin®) had
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum
Posted on Wednesday April 10, 2024
SAN DIEGO, April 10, 2024--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today announced that David Urso, president and chief executive officer of MEI Pharma, will participate in a fireside chat at the Stifel 2024 Virtual Targeted Oncology Forum on Tuesday, April 16 at 1:30 PM Eastern Time.
MEI Pharma Reports Update from Clinical Study Evaluating Oral CDK9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia
Posted on Tuesday March 26, 2024
SAN DIEGO, March 26, 2024--MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported initiation of enrollment in a 12-patient expansion cohort in the ongoing Phase 1 study evaluating voruciclib, an investigational selective oral cyclin-dependent kinase 9 ("CDK9") inhibitor, in combination with venetoclax (Venclexta®), a B-cell lymphoma 2 ("BCL2") inhibitor,